In conclusion, we herein show that the majority of GBM patients exhibits expression of the biologically active form of the tyrosine receptor AXL in distinct parts of the tumor, indicating that GBMs might be susceptible for anti-AXL therapy. The gene discussed is AXL; the disease is neoplasm.